Business
FDA panel knocks down Pfizer, Lilly’s osteoarthritis pain drug in near-unanimous vote – FierceBiotech
After dozens of trials over more than 15 years, Pfizer and Eli Lilly’s osteoarthritis hopeful was poised for an FDA decision in December 2020—that is, until the…
After dozens of trials over more than 15 years, Pfizer and Eli Lillys osteoarthritis hopeful was poised for an FDA decision in December 2020that is, until the agency called a panel of outside experts to chew over the drugs application. That panel came down against the drug in a vote on Thursday because of major safety risks and an inadequate plan to manage them.
The Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee voted 19-1 that a drug safety strategy proposed…
-
Noosa News17 hours agoBrisbane vs Collingwood live blog: Richmond selects Noah Balta as unbeaten Lions prepare for Magpies test
-
General24 hours agoMinecraft mayhem: ‘Chicken jockey’ chaos reaches Australian cinemas
-
General16 hours agoNT Coalition candidate Lisa Siebert diverges from Jacinta Nampijinpa Price on royal commission call
-
General18 hours agoCanberra man named as doctor accused of rape after suppression order lifted